Cargando…

Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation

• Molecular testing may play a role in the determination of targeted therapy treatment options. • Targeted therapy provides treatment options for recurrent cervical cancer. • MEK inhibitor is a treatment option for recurrent cervical cancer in a patient with KRAS mutation.

Detalles Bibliográficos
Autores principales:	Lyons, Yasmin A., Frumovitz, Michael, Soliman, Pamela T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4434143/ https://www.ncbi.nlm.nih.gov/pubmed/26075998 http://dx.doi.org/10.1016/j.gore.2014.09.003

Ejemplares similares

Comparative genomics of high grade neuroendocrine carcinoma of the cervix
por: Hillman, R. Tyler, et al.
Publicado: (2020)

Isolated subcutaneous recurrence of high-grade neuroendocrine tumor of the cervix
por: Bos, Lia, et al.
Publicado: (2021)

Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
por: Bayrak, Omer, et al.
Publicado: (2014)

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS(G12R)-mutant pancreatic ductal adenocarcinoma
por: Kenney, Cara, et al.
Publicado: (2021)

Neuroendocrine small cell carcinoma of the cervix: A case report
por: Giordano, Giovanna, et al.
Publicado: (2021)

RB1 alteration and poor prognosis in women with high-grade neuroendocrine carcinoma of the uterine cervix: a NeCTuR study
por: Flores Legarreta, Alejandra, et al.
Publicado: (2023)

Large-cell neuroendocrine carcinoma of the cervix
por: Yoseph, Benyam, et al.
Publicado: (2012)

Neuroendocrine carcinoma of cervix and review literature
por: Verma, Saransh, et al.
Publicado: (2023)

Association between KRAS mutation and lung metastasis in advanced colorectal cancer
por: Pereira, A A L, et al.
Publicado: (2015)

Whole exome sequencing identifies common mutational landscape of cervix and endometrium small cell neuroendocrine carcinoma
por: Wang, Wei, et al.
Publicado: (2023)

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
por: Xu, J, et al.
Publicado: (2017)

Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
por: Prado, C M M, et al.
Publicado: (2012)

MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer
por: Fanini, Francesca, et al.
Publicado: (2021)

Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)
por: Santin, Alessandro D., et al.
Publicado: (2020)

Diagnostic value of four neuroendocrine markers in small cell neuroendocrine carcinomas of the cervix: a meta-analysis
por: Huang, Rui, et al.
Publicado: (2020)

Neuroendocrine Carcinoma of Cervix: A Case Series
por: Tangella, Adarsh Vardhan, et al.
Publicado: (2023)

Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report
por: Paraghamian, Sarah E., et al.
Publicado: (2017)

Cytological features of adenocarcinoma admixed with small cell neuroendocrine carcinoma of the uterine cervix
por: Shimojo, Naoshi, et al.
Publicado: (2017)

Small Cell Neuroendocrine Carcinoma of the Cervix in Pregnancy: A Case Report and Review
por: Pan, Linglan, et al.
Publicado: (2019)

Small cell neuroendocrine carcinoma of the cervix: Analysis of prognostic factors and patterns of metastasis
por: Gordhandas, Sushmita, et al.
Publicado: (2022)

Small Cell (Neuroendocrine) Carcinoma of the Cervix: An Analysis for 19 Cases and Literature Review
por: Lu, JunLing, et al.
Publicado: (2022)

Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances
por: Chao, Angel, et al.
Publicado: (2023)

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
por: Jänne, P A, et al.
Publicado: (2015)

MEK inhibition suppresses metastatic progression of KRAS‐mutated gastric cancer
por: Yamasaki, Juntaro, et al.
Publicado: (2022)

Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing()
por: Rose, Peter G., et al.
Publicado: (2019)

Small cell neuroendocrine carcinoma with adenocarcinoma and high grade squamous intraepithelial neoplasia of the cervix
por: Gurubalan, Guralarasan, et al.
Publicado: (2023)

Neuroendocrine carcinoma of the cervix: a systematic review of the literature
por: Tempfer, Clemens B., et al.
Publicado: (2018)

Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS‐mutated ovarian cancer cells with high AXL expression
por: Umemura, Shiori, et al.
Publicado: (2020)

Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix
por: Donaldson, S B, et al.
Publicado: (2010)

The Treatment of Carcinoma of the Cervix
por: Hardon, Virgil O.
Publicado: (1903)

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
por: Gelsomino, Francesco, et al.
Publicado: (2021)

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models
por: Zhou, XuSha, et al.
Publicado: (2021)

High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients
por: Ilm, Katharina, et al.
Publicado: (2015)

Breast cancer and ductal carcinoma in situ among women with prior squamous or glandular precancer in the cervix: a register-based study
por: Hansen, B T, et al.
Publicado: (2012)

Small cell neuroendocrine carcinoma of the uterine cervix presenting with syndrome of inappropriate antidiuretic hormone secretion
por: Kim, Do Young, et al.
Publicado: (2013)

Malignant Müllerian Mixed Tumor of the Uterine Cervix with a Small Cell Neuroendocrine Carcinoma Component
por: Munakata, Satoru, et al.
Publicado: (2013)

A Nomogram Model Based on Neuroendocrine Markers for Predicting the Prognosis of Neuroendocrine Carcinoma of Cervix
por: Jia, Mingzhu, et al.
Publicado: (2023)

Assessment of intrafractional motion of the cervix–uterus by MR-guided radiotherapy system
por: Nagao, Ayaka, et al.
Publicado: (2023)

Leptomeningeal metastasis from neuroendocrine carcinoma of the cervix: illustrative case
por: Patterson, John D., et al.
Publicado: (2023)

Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours
por: Korse, C M, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_i4spthmkknf6nu9jo3okccvif8